Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial — Aldo Maggioni (2013) | RDL Network
Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial
This pre-specified subgroup analysis from the ASTRONAUT trial generates the hypothesis that the addition of aliskiren to standard HHF therapy in non-diabetic patients is generally well-tolerated and improves post-discharge outcomes and biomarker profiles. In contrast, diabetic patients receiving aliskiren appear to have worse post-discharge outcomes. Future prospective investigations are needed to confirm potential benefits of renin inhibition in a large cohort of HHF patients without DM.
Muthiah Vaduganathan, Baljash Cheema, Erin R. Cleveland, K. Nathan Sankar, Haris Subačius, Gregg C. Fonarow, Scott D. Solomon, Eldrin F. Lewis, Stephen J. Greene, Aldo Maggioni, Michael Böhm, Faı̈ez Zannad, Javed Butler, Mihai Gheorghiade
Muthiah Vaduganathan, Baljash Cheema, Erin R. Cleveland, K. Nathan Sankar, Haris Subačius, Gregg C. Fonarow, Scott D. Solomon, Eldrin F. Lewis, Stephen J. Greene, Aldo Maggioni, Michael Böhm, Faı̈ez Zannad, Javed Butler, Mihai Gheorghiade
Stephen J. Greene, Gregg C. Fonarow, Scott D. Solomon, Haris Subačius, Andrew P. Ambrosy, Muthiah Vaduganathan, Aldo Maggioni, Michael Böhm, Eldrin F. Lewis, Faı̈ez Zannad, Javed Butler, Mihai Gheorghiade
Stephen J. Greene, Faı̈ez Zannad, Gregg C. Fonarow, Haris Subačius, Marco Triggiani, Andrew P. Ambrosy, Michael Böhm, Javed Butler, Ovidiu Chioncel, Aldo Maggioni, Scott D. Solomon, Muthiah Vaduganathan, Mihai Gheorghiade, Michele Senni
Satyam Sarma, Robert J. Mentz, Mary Kwasny, Angela J. Fought, Mark D. Huffman, Haris Subačius, Savina Nodari, Marvin A. Konstam, Karl Swedberg, Aldo Maggioni, Faı̈ez Zannad, Robert O. Bonow, Mihai Gheorghiade
Discussion(0)
No comments yet. Be the first to comment.